Company
Rakovina Therapeutics, Inc.
United States
Market Cap
C$6.3 Million
CAD as of Jan. 1, 2024
US$4.7 Million
Rakovina Therapeutics, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Rakovina Therapeutics Inc., a biopharmaceutical company, focuses on development of cancer treatments based on novel DNA-damage response technologies. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. The company's lead pipeline products include kt-2000 Next Generation PARP-inhibitors; kt-3000 Dual Action DDR-inhibitors; and kt-4000 DNA Damaging DDR-inhibitors. Rakovina Therapeutics was founded in 2020 and is headquartered in Vancouver, Canada.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Rakovina Therapeutics, Inc. has the following listings and related stock indices.
Stock: TSXV: RKV wb_incandescent